Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Zariana Nikolova Margaret von Mehren Michael C. Heinrich Heikki Joensuu George D Demetri |
| Publication date | February 1, 2008 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |